This webinar is for UK HCPs only and has been developed and organised by Seqirus.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events relating to Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
Click below for prescribing information;
Fluad® Tetra 
, Adjuvanted quadrivalent influenza vaccine (surface antigen, inactivated): https://labeling.seqirus.com/API/UK/FluAd-Tetra/EN/FluAd-Tetra-Prescribing-Information.pdf
Fluad® (influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1): https://labeling.seqirus.com/API/UK/Fluad/EN/Fluad-Prescribing-Information.pdf
Adjuvanted Trivalent Influenza Vaccine (aTIV) (surface antigen, inactivated): https://labeling.seqirus.com/API/UK/aTIV/EN/aTIV-Prescribing-Information.pdf